These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 34757069)
1. STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma. Dzung A; Saltari A; Tiso N; Lyck R; Dummer R; Levesque MP J Invest Dermatol; 2022 Apr; 142(4):1171-1182.e10. PubMed ID: 34757069 [TBL] [Abstract][Full Text] [Related]
2. STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications. Azin M; Demehri S J Invest Dermatol; 2022 Apr; 142(4):1007-1009. PubMed ID: 35131083 [TBL] [Abstract][Full Text] [Related]
3. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
4. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor. Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109 [TBL] [Abstract][Full Text] [Related]
5. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Burd CE; Liu W; Huynh MV; Waqas MA; Gillahan JE; Clark KS; Fu K; Martin BL; Jeck WR; Souroullas GP; Darr DB; Zedek DC; Miley MJ; Baguley BC; Campbell SL; Sharpless NE Cancer Discov; 2014 Dec; 4(12):1418-29. PubMed ID: 25252692 [TBL] [Abstract][Full Text] [Related]
6. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422 [TBL] [Abstract][Full Text] [Related]
7. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters. Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187 [TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma. Del Mistro G; Riemann S; Schindler S; Beissert S; Kontermann RE; Ginolhac A; Halder R; Presta L; Sinkkonen L; Sauter T; Kulms D Cell Death Dis; 2022 Jan; 13(1):54. PubMed ID: 35022419 [TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196 [TBL] [Abstract][Full Text] [Related]
10. KIT Suppresses BRAF Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418 [TBL] [Abstract][Full Text] [Related]
11. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Vultur A; Villanueva J; Krepler C; Rajan G; Chen Q; Xiao M; Li L; Gimotty PA; Wilson M; Hayden J; Keeney F; Nathanson KL; Herlyn M Oncogene; 2014 Apr; 33(14):1850-61. PubMed ID: 23624919 [TBL] [Abstract][Full Text] [Related]
12. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523 [TBL] [Abstract][Full Text] [Related]
13. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195 [TBL] [Abstract][Full Text] [Related]
14. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related]
15. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424 [TBL] [Abstract][Full Text] [Related]
16. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787 [TBL] [Abstract][Full Text] [Related]
17. Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage. Taylor KN; Schlaepfer DD Mol Cancer Ther; 2018 Apr; 17(4):719-723. PubMed ID: 29610281 [TBL] [Abstract][Full Text] [Related]
18. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy. Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776 [TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947 [TBL] [Abstract][Full Text] [Related]
20. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Jain A; Tripathi R; Turpin CP; Wang C; Plattner R Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]